CN101166981A - 一种用于诊断 2型糖尿病、代谢综合征、亚临床动脉粥样硬化、心肌梗死、中风或糖尿病的临床表现的方法和试剂盒 - Google Patents

一种用于诊断 2型糖尿病、代谢综合征、亚临床动脉粥样硬化、心肌梗死、中风或糖尿病的临床表现的方法和试剂盒 Download PDF

Info

Publication number
CN101166981A
CN101166981A CNA2006800144529A CN200680014452A CN101166981A CN 101166981 A CN101166981 A CN 101166981A CN A2006800144529 A CNA2006800144529 A CN A2006800144529A CN 200680014452 A CN200680014452 A CN 200680014452A CN 101166981 A CN101166981 A CN 101166981A
Authority
CN
China
Prior art keywords
sdldl
particle
diabetes
study subject
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800144529A
Other languages
English (en)
Chinese (zh)
Inventor
G·卡梅乔
P·戴维森
J·赫尔塞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN101166981A publication Critical patent/CN101166981A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CNA2006800144529A 2005-04-11 2006-04-10 一种用于诊断 2型糖尿病、代谢综合征、亚临床动脉粥样硬化、心肌梗死、中风或糖尿病的临床表现的方法和试剂盒 Pending CN101166981A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE05008081 2005-04-11
SE0500808 2005-04-11

Publications (1)

Publication Number Publication Date
CN101166981A true CN101166981A (zh) 2008-04-23

Family

ID=37087285

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800144529A Pending CN101166981A (zh) 2005-04-11 2006-04-10 一种用于诊断 2型糖尿病、代谢综合征、亚临床动脉粥样硬化、心肌梗死、中风或糖尿病的临床表现的方法和试剂盒

Country Status (5)

Country Link
US (1) US20090280501A1 (https=)
EP (1) EP1872138A1 (https=)
JP (1) JP2008538812A (https=)
CN (1) CN101166981A (https=)
WO (1) WO2006110082A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102565416A (zh) * 2010-12-27 2012-07-11 中国科学院上海生命科学研究院 载脂蛋白a1作为糖尿病标志物的应用
CN103376323A (zh) * 2012-04-25 2013-10-30 中国科学院上海生命科学研究院 载脂蛋白c-iii作为肥胖型糖尿病标志物的应用
CN103620404A (zh) * 2011-06-27 2014-03-05 碧奥克里内股份公司 用于治疗糖尿病和/或限制糖尿病发展的方法
CN107884467A (zh) * 2017-10-31 2018-04-06 北京毅新博创生物科技有限公司 改善质谱检测糖基结晶的方法及产品

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2517572C (en) * 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
EP2015077B1 (en) * 2006-05-01 2012-10-31 DENKA SEIKEN Co., Ltd. Method for detection of familial combined hyperlipidemia
JP2008116248A (ja) * 2006-11-01 2008-05-22 Yoshikimi Kikuchi 子宮体癌の検出方法
AT505727B1 (de) * 2007-09-04 2009-06-15 Univ Innsbruck Verfahren zur diagnose des metabolischen syndroms
KR20110086074A (ko) * 2008-10-20 2011-07-27 리포사이언스, 인크. 지질단백질 인슐린 저항성 지표 및 이와 관련된 방법, 시스템 및 이를 생성하기 위한 컴퓨터 프로그램
JP2010190804A (ja) * 2009-02-19 2010-09-02 Biomarker Science:Kk 動脈硬化改善・予防効果の評価方法及び評価用キット、並びに、物質のスクリーニング方法
US20110008901A1 (en) * 2009-07-07 2011-01-13 Kiernan Urban A Apolipoprotein ciii in pre- and type 2 diabetes
CN103299192B (zh) * 2010-09-21 2016-05-11 普罗蒂阿米克斯国际有限公司 与糖尿病前期、糖尿病以及糖尿病相关病症相关的生物标记
KR101355394B1 (ko) 2011-08-03 2014-01-29 서울대학교산학협력단 임신성 당뇨 조기 진단 정보를 제공하는 방법 및 임신성 당뇨 조기 진단 정보를 제공하는데 사용되는 임신성 당뇨 모니터링, 진단 및 스크리닝용 키트
CN103308670B (zh) * 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064008A2 (en) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccine for the treatment of artherosclerosis
US20040137521A1 (en) * 2001-06-05 2004-07-15 Jamila Najib-Fruchart Method for apo clll measurement in apo b and non apo b containing particles
JP4593026B2 (ja) * 2001-07-18 2010-12-08 栄研化学株式会社 ＳｍａｌｌｄｅｎｓｅＬＤＬの測定方法
WO2003029829A1 (en) * 2001-10-01 2003-04-10 The Texas A & M University System Lipoprotein fingerprinting method
ATE505731T1 (de) * 2002-12-06 2011-04-15 Denka Seiken Kk Verfahren zur quantifizierung von kleinen lipoproteinen mit geringer dichte

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102565416A (zh) * 2010-12-27 2012-07-11 中国科学院上海生命科学研究院 载脂蛋白a1作为糖尿病标志物的应用
CN103620404A (zh) * 2011-06-27 2014-03-05 碧奥克里内股份公司 用于治疗糖尿病和/或限制糖尿病发展的方法
CN103620404B (zh) * 2011-06-27 2016-03-30 碧奥克里内股份公司 用于治疗糖尿病和/或限制糖尿病发展的方法
CN103376323A (zh) * 2012-04-25 2013-10-30 中国科学院上海生命科学研究院 载脂蛋白c-iii作为肥胖型糖尿病标志物的应用
CN107884467A (zh) * 2017-10-31 2018-04-06 北京毅新博创生物科技有限公司 改善质谱检测糖基结晶的方法及产品

Also Published As

Publication number Publication date
US20090280501A1 (en) 2009-11-12
WO2006110082A1 (en) 2006-10-19
JP2008538812A (ja) 2008-11-06
EP1872138A1 (en) 2008-01-02

Similar Documents

Publication Publication Date Title
Begue et al. Altered high-density lipoprotein composition and functions during severe COVID-19
Sun et al. Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease
EP1423705B1 (en) Conjunctive analysis of biological marker expression for diagnosing organ failure
US9933439B2 (en) Method of predicting acute appendicitis
CN101166981A (zh) 一种用于诊断 2型糖尿病、代谢综合征、亚临床动脉粥样硬化、心肌梗死、中风或糖尿病的临床表现的方法和试剂盒
EP2281203B1 (en) A marker for graft failure and mortality
Mir et al. Plasma concentrations of N-terminal brain natriuretic peptide in healthy children, adolescents, and young adults: effect of age and gender
EP2376919B1 (en) Combined natriuretic peptide assays
US20070099242A1 (en) Lipoprotein-associated markers for cardiovascular disease
US8663931B2 (en) Method for detecting renal disease comprising measuring human megalin in urine
US20100086944A1 (en) Methods and Compositions for Diagnosis and Prognosis of Renal Artery Stenosis
US20140322723A1 (en) Diabetes diagnosis through the detection of glycated proteins in urine
EP3499230A1 (en) Method for assisting diagnosis of alzheimer's disease using urine biomarker
US20220178945A1 (en) Novel aortic aneurysm marker
Santiago-Hernandez et al. Early renal and vascular damage within the normoalbuminuria condition
US20130143806A1 (en) Method for early prognosis of kidney disease
WO2012146778A2 (en) Method for indicating a renal disease in a patient
JP2013504751A (ja) 血管疾患を診断および評価するためのポリペプチドマーカー
EP3951387A1 (en) Arteriosclerosis and arteriosclerosis-related disease marker
KR101160153B1 (ko) 체액 내 베타-아밀로이드 자가항체의 농도를 측정하여 제2형 당뇨병을 진단하는 방법 및 이를 이용한 제2형 당뇨병 진단키트
Xu et al. Clinical significance of UbA52 level in the urine of patients with type 2 diabetes mellitus and diabetic kidney disease
Nuvolone et al. AL or ATTR amyloidosis? Never two without three
CN118011012B (zh) LL-37-ApoB-100生物标志物及其应用
CN100543471C (zh) 组织缺氧的体液指标
US20130115633A1 (en) Methods & Devices for Diagnosing Cardiac Disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080423